World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 11 January 2021
Main ID:  EUCTR2015-000400-26-IT
Date of registration: 10/11/2020
Prospective Registration: No
Primary sponsor: GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
Public title: A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren's syndrome
Scientific title: A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subjects with primary Sjögren's syndrome. - NA
Date of first enrolment: 18/01/2016
Target sample size: 120
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000400-26
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: yes
Other trial design description: Sponsor unblinded
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: yes
Other: no
Number of treatment arms in the trial: 4
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Argentina Canada France Germany Italy Netherlands Norway Spain
Sweden United Kingdom
Contacts
Name: GSK Clinical Support Help Desk   
Address:  Iron Bridge Road UB11 1BU Uxbridge United Kingdom
Telephone: 004408007839733
Email: GSKClinicalSupportHD@gsk.com
Affiliation:  GlaxoSmithKline Research & Development Ltd
Name: GSK Clinical Support Help Desk   
Address:  Iron Bridge Road UB11 1BU Uxbridge United Kingdom
Telephone: 004408007839733
Email: GSKClinicalSupportHD@gsk.com
Affiliation:  GlaxoSmithKline Research & Development Ltd
Key inclusion & exclusion criteria
Inclusion criteria:
AGE
1. Age =18 years, at the time of signing the informed consent.
TYPE OF SUBJECT AND DIAGNOSIS INCLUDING DISEASE SEVERITY
2. Documented Primary Sjögren's Syndrome by American European Consensus Group criteria including:
- either SS-A or SS-B positive.
3. Baseline unstimulated salivary flow >0.0 mL/min or evidence of glandular reserve function (stimulated baseline salivary flow >0.05 mL/min).
4. Symptomatic oral dryness (=5/10 on subject completed Numeric Response Scale)
5. Systemically active disease, ESSDAI=5 points and with at least:
a) 1 extraglandular domain moderate,
OR
b) 2 extraglandular domains low.
SEX
6. Male and female subjects; females of child bearing potential are eligible if using effective contraception:Female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotropin (hCG) test), not lactating, and at least one of the following conditions applies:
a. Non-reproductive potential defined as:
-Pre-menopausal females with one of the following:
-Documented tubal ligation
-Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
-Hysterectomy
-Documented Bilateral Oophorectomy
- Postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating
hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study; otherwise,
they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
b. Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication up to Week 68 after Day 0.
GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP)
This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to
be abstinent from penilevaginal intercourse on a long term and persistent basis.
-Contraceptive subdermal implant that meets the SOP effectiveness criteria including a <1% rate of failure per year, as stated in the product label
-Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a <1% rate of failure per year, as stated in the product label
-Oral Contraceptive, either combined or progestogen alone
-Injectable progestogen
-Contraceptive vaginal ring
-Percutaneous contraceptive patches
-Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject.
-Male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository).
These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label.
The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adult

Exclusion criteria:
1. Diagnosis of secondary Sjögren's syndrome.
2. Active life-threatening or organ-threatening complications of SS disease at the time of screening based on treating physician evaluation including but not restricted to (a) vasculitis with renal, digestive, cardiac, pulmonary or CNS involvement characterized as severe, (b) active CNS or PNS involvement requiring high dose steroids, (c) severe
renal involvement defined by objective measures, (d) lymphoma.
3. History of major organ transplant
4. History of malignancy within past 5 years [with the exception of adequately treated:
(a) cervical carcinoma Stage 1B or less, (b) non-invasive basal cell and squamous cell skin carcinoma].
5. History of infection requiring long term systemic therapy including:
(a) history of positive HIV serology, (b) positive serology for Hepatitis C (HCV), (c) positive
serology for Hepatitis B (HB), defined as: (i) HB surface antigen positive (HBsAg+) OR (ii) HB core antibody positive (HBcAb+).
6. Previous serious opportunistic or atypical infections or hospitalization for treatment of infection within 364 days of Day 0 or use of parenteral
(IV or IM) antibacterials, antivirals, anti-fungals, or anti-parasitic agents within 364 days of prior to Day 0.
7. Patients in a severely immunocompromised state.
8. History of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
9. History of significant medical illness which in the opinion of the investigator would interfere with the study procedures and / or assessments - including but not limited to IgG4 disease or prior head or
neck irradiation.
10. Severe heart failure or other severe, uncontrolled cardiac disease.
11. Tuberculosis (TB), defined as: (a) prior history of TB infection, (b) suspicion of TB infection or (c) current TB infection
12. At risk of suicide, as indicated by a lifetime history of attempted suicide or significant suicidal ideation over the 6 months prior to the
screening visit; or, if in the Investigator's judgment, the subject is at risk for a suicide attempt.
13. Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML) - not otherwise explained - or confirmed PML.
14. Electrocardiogram (ECG) showing a clinically significant abnormality at Screening or showing an average QTcB or QTcF interval =450 msec over 3 consecutive ECGs
15. ALT >2xULN and bilirubin >1.5xULN
16. Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
CONCOMITANT MEDICATIONS
17. Use of systemic immunosuppressive or immunomodulatory agents including
methotrexate, azathioprine, leflunomide, mycophenolate, mizoribine, calcineurin inhibitors, sirolimus, 6-mercaptopurine, or thalidomide)
within 60 days prior to Day 0.
18. Have received cyclophosphamide within 180 days prior to Day 0.
19. Have received anti-BLyS, anti-CD 20, anti-CD22 or anti-CD52 or any other B-cell depleting agent within 364 days prior to Day 0.
For the remaining exclusion criteria refer to the corresponding section in the protocol.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Primary Sjogrens disease
MedDRA version: 20.0 Level: PT Classification code 10061664 Term: Autoimmune disorder System Organ Class: 10021428 - Immune system disorders
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Intervention(s)

Trade Name: MABTHERA - 1 FIALA 500 MG 50 ML
Product Name: MABTHERA
Product Code: [NA]
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: RITUXIMAB
CAS Number: 174722-31-7
Current Sponsor code: NA
Other descriptive name: MABTHERA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Trade Name: BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO
Product Name: BENLYSTA
Product Code: [na]
Pharmaceutical Form: Solution for injection
INN or Proposed INN: BELIMUMAB
CAS Number: 356547-88-1
Current Sponsor code: GSK1550188
Other descriptive name: HGS1006, LymphoStat-B, monoclonal anti-BLyS, LSB, BENLYSTA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use

Trade Name: SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML
Product Name: SOLU-MEDROL
Product Code: [na]
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: METILPREDNISOLONE
Current Sponsor code: NA
Concentration unit: µg/ml microgram(s)/millilitre
Concentration type: equal
Concentration number: 62500-

Trade Name: TACHIPIRINA - 500 MG COMPRESSE20 COMPRESSE
Product Name: Tachipirina
Product Code: [na]
Pharmaceutical Form: Tablet
INN or Proposed INN: PARACETAMOLO
Current Sponsor code: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 500-

Trade Name: XYZAL - 20 COMPRESSE RI
Primary Outcome(s)
Main Objective: Safety and tolerability of anti-BLyS / anti-CD 20 coadministration therapy and anti-BLyS and anti-CD 20 monotherapies
Primary end point(s): Safety and tolerability
Secondary Objective: - Clinical efficacy of anti-BLyS / anti-CD 20 co-administration therapy and anti-BLyS and anti-CD 20 monotherapies
- Assessment of anti-BLyS / anti-CD 20 co administration therapy and anti-BLyS and anti-CD 20 monotherapies on tissue B-cells.
Timepoint(s) of evaluation of this end point: Weeks 24 and 52
Secondary Outcome(s)
Secondary end point(s): ESSDAI score; stimulated salivary flow; oral dryness numeric response scale; B cell quantification within the salivary gland
Timepoint(s) of evaluation of this end point: Weeks 24 and 52
Secondary ID(s)
2015-000400-26-SE
201842
Source(s) of Monetary Support
GlaxoSmithKline R&D
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 05/11/2015
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history